NYSE · BAX

Baxter International Inc.

$23.34 +$0.94 (+4.20%) 1D After hours

Key Metrics

$11.57B
Market cap
P/E · TTM
$11.32B
Revenue · TTM
−$1.10B
Net income
EPS · TTM $-2.14
Dividend yield 2.3%
Free cash flow
Beta · 1Y 1.13
EBITDA · TTM $463.00M
Gross margin 30.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 30
    From its Feb 11 high, the share price fell 29%.

    Peak close $22.27 on Feb 11; trough close $15.80 on Mar 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -29%
  • Feb 12
    The stock moved -16.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 12

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$11.57B
Enterprise value$10.39B
Shares outstanding516.5M
52-wk range$15.73 – $29.00
Avg volume · 20D4.7M
Net cash $1.18B
Book value / share$11.76
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNYSE
About Baxter International Inc.
IPO dateMay 15, 1961
Employees37500

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.02
P/FCF
EV/EBITDA22.45
EV/Sales0.92
Graham №

Profitability

Gross 30.1%
Operating -4.5%
Net -9.7%
FCF
ROE / ROIC -16.9% · -20.2%

Financial Health

Current ratio1.85
Quick ratio1.23
Debt / equity0.14
Debt / EBITDA 1.82
Net cash $1.18B
Working capital$3.15B

Cash Flow · TTM

Operating CF $1.25B
Capex
Free cash flow
Buybacks
Dividends paid $266.00M
Shareholder yield 2.3%

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

2.1
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings